Vanda inks $11.5M deal to settle off-label drug promotion accusations

Nicole DeFeudis

Editor

Vanda Pharmaceuticals took the FDA to court three separate times this year as it struggles to win over regulators with its sleep and chronic digestive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vanda inks $11.5M deal to settle off-label drug promotion accusations

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Van­da inks $11.5M deal to set­tle off-la­bel drug pro­mo­tion ac­cu­sa­tions

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Vanda inks $11.5M deal to settle off-label drug promotion accusations